The multifaceted activity profile of PPARα/γ agonists in tumor tissue may be best exemplified in leukemia, both, in chronic myelocytic leukemias in combination with imatinib and in acute leukemias in combination with ATRA and low dose azacitidine (7, 25, 103, 116, 117). The gene discussed is PPARA; the disease is neoplasm.